Jinhai Medical Technology Full Year 2024 Earnings: S$0.003 loss per share (vs S$0.001 loss in FY 2023)

Jinhai Medical Technology (HKG:2225) Full Year 2024 Results

Key Financial Results

• Revenue: S$50.2m (up 10% from FY 2023).
• Net loss: S$18.0m (loss widened by 472% from FY 2023).
• S$0.003 loss per share (further deteriorated from S$0.001 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Products segment contributing a total revenue of S$25.9m (52% of total revenue). Notably, cost of sales worth S$38.8m amounted to 77% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to S$31.6m (100% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of S$2.12m. Explore how 2225's revenue and expenses shape its earnings.

Jinhai Medical Technology's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Jinhai Medical Technology.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.